Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer.

Cancers (Basel) · 2022 · PMC8869800 · PMID 35205763

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

trending towards significancep = 0.06so close (0.05 < p ≤ 0.1)

Moreover, control tumors had 72.1 ± 26.3% hypoxic fraction on day 7, while tumors treated with trastuzumab had a reduced hypoxic fraction, trending towards significance, of 30.6 ± 34.6% on day 7 ( p = 0.06).

also in 515 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.